Tradestie Institutional Equity Comparison Engine

MBIO vs FBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FBIO Overall Edge

FBIO Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Fortress Biotech, Inc. (FBIO) driven by superior Valuation, Growth & Margin, Options & Structure while MBIO counters with relative strength in Momentum & Technical. Fundamentally, MBIO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FBIO at 1.2x Forward P/E and -42.8% operating margin (+8.7% YoY). In options structure, MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against FBIO sits in BREAKDOWN (41st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner FBIO
MBIO N/M vs FBIO 1.2x Fwd P/E
Growth & Margin Winner FBIO
Op Margin 0.0% vs -42.8% ยท YoY +0.0% vs +8.7%
Momentum & Technical Winner MBIO
1Y -67.4% vs -31.3% ยท 52W Pos 4% vs 0%
Options & Structure Winner FBIO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (41st %ile IV)
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
1M Return +4.86%
1Y Return -67.38%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
FBIO NASDAQ
Fortress Biotech, Inc.
Pharmaceutical Preparations
$1.71
-9.04% 1D
Market Cap $62.7M
1M Return -8.56%
1Y Return -31.33%
Forward P/E 1.2x
Unified AI Score
50.4 / 100 HOLD
Tech 21.0 Fund 51.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MBIO -67.38% FBIO -31.33% Spread: +36.05 pp (FBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MBIO TTM Op. Margin: 0.0% FBIO TTM Op. Margin: -42.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs FBIO. Trailing 12-month operating profitability (MBIO 0.0% vs FBIO -42.8%) and valuation multiples (MBIO N/M vs FBIO 1.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MBIO (2) vs FBIO (8)
Institutional Metric MBIO FBIO Criterion Row Winner
Market Capitalization Scale $3.2M $62.7M Larger Scale FBIO
Trailing P/E Ratio Valuation N/M 0.7x Lower Multiple FBIO
Forward P/E Ratio Valuation N/M 1.2x Lower Multiple FBIO
Revenue Growth (YoY) Growth +0.0% +8.7% Higher Growth FBIO
Operating Margin (TTM) Profitability 0.0% -42.8% Higher Margin MBIO
Net Profit Margin Profitability 0.0% 143.1% Higher Margin FBIO
Return on Equity (ROE) Capital Efficiency -43.1% 102.5% Higher ROE FBIO
52-Week Range Position Momentum 4% ($0โ€“$1) 0% ($2โ€“$5) Stronger Trend MBIO
Beta / 30D Volatility Risk Regime 0.66ฮฒ ยท 86% Vol 1.24ฮฒ ยท 64% Vol Lower Realized Risk FBIO
Unified Institutional Score Composite Signal 42.9 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite FBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MBIO vs FBIO Buy Guide
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FBIO BREAKDOWN
88d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 41st %ile
IV Regime Balanced (25thโ€“60th %ile)
Live FBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MBIO nor FBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.